Video

Why PSMA imaging is unique from other prostate cancer imaging technologies

Author(s):

Urology Times staff

We've never had an imaging agent like this before,” says Leonard S. Marks, MD.

In this video, Leonard S. Marks, MD, gives an overview of the Journal of Urology review on prostate-specific antigen membrane imaging for prostate cancer. He details how this technology will affect the detection and treatment of patients with this disease and is hopeful of its real-world application in the future. Marks is a deKernion Endowed Chair in Urology at the David Geffen School of Medicine at the University of California, Los Angeles.

Related Videos
Conceptual image for prostate cancer treatment | Image Credit: © Dr_Microbe - stock.adobe.com
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
David I. Lee, MD, FACS, answers a question during a video interview
Todd M. Morgan, MD, answers a question during a Zoom video interview
Related Content
Bridget Koontz, MD: 18F-flotufolastat demonstrates high detection rate in low PSA setting
October 10th 2024

Bridget Koontz, MD: 18F-flotufolastat demonstrates high detection rate in low PSA setting

Urology Times staff
"We found that as soon as we got to the range of biochemical recurrence-defined PSA—0.2 ng/mL and up—the detection rate was very high," says Bridget Koontz, MD, FASTRO.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Urology Times staff
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Senior doctor asking elderly patient questions | Image Credit: © rocketclips - stock.adobe.com
October 7th 2024

Wayne G. Brisbane, MD, discusses AI-assisted HIFU for prostate cancer

Urology Times staff
"I think it's a really nice synergy between the 2 technologies," says Wayne G. Brisbane, MD.
Unlocking the potential of PSMA-PET: The need for interdisciplinary collaboration in image interpretation
Published: October 4th 2024 | Updated: October 4th 2024

Unlocking the potential of PSMA-PET: The need for interdisciplinary collaboration in image interpretation

Urology Times staff
"The radiologist more than ever has to be part of the care team," says Phillip H. Kuo, MD, PhD, FACR.
Study to compare TLX250-CDx vs contrast-enhanced CT for recurrent ccRCC
October 4th 2024

Study to compare TLX250-CDx vs contrast-enhanced CT for recurrent ccRCC

Hannah Clarke
“We are pleased that a first patient has been imaged in the CA-NINE trial, which supports potential label expansion for TLX250-CDx into recurrent, metastatic disease,” says David N. Cade.
Collaboration aims to streamline prostate MRI interpretation, fusion biopsy guidance
September 25th 2024

Collaboration aims to streamline prostate MRI interpretation, fusion biopsy guidance

Hannah Clarke
With this integration, imaging data from the DeepHealth software can be readily imported to the Trinity 3D Ultrasound Platform for prostate fusion biopsy.
© 2024 MJH Life Sciences

All rights reserved.